Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: Data from three clinical trials

International Journal of Clinical Practice

Volumn 64, Issue 2, 2010, Pages 188-193

  Sadowsky, C H ^a   Farlow, M R ^b   Meng, X ^c   Olin, J T ^c  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; RIVASTIGMINE;

AGED; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DEMENTIA; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DIZZINESS; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; SYNCOPE; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; ALZHEIMER DISEASE; BLOOD PRESSURE; CAPSULES; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; MALE; PHENYLCARBAMATES; PIPERIDINES; PULSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATION;

EID: 72449153455     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02253.x     Document Type: Article

References (18)

1. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001 56 : 1154 1166.
2. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999 318 : 633 638.
3. Exelon® Patch (rivastigmine transdermal system) Prescribing Information. http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf (accessed November 2009).
4. Winblad B, Grossberg G, Frolich L et al. IDEAL: a 6 month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007 69 : S14 22.
5. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009 2 : CD001191.
6. Sadowsky CH, Farlow MR, Atkinson L, et al. Switching From donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study. Prim Care Companion J Clin Psychiatry 2005 7 : 43 48.
7. Figiel GS, Sadowsky CH, Strigas J, Koumaras B, Meng X, Gunay I. Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study. Prim Care Companion J Clin Psychiatry 2008 10 : 291 298.
8. Sadowsky C, Dengiz A, Olin J, Koumaras B, Meng X, Brannan S. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alzheimer Dis Other Demen 2009 24 : 267 275.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA : American Psychiatric Press, Inc., 1994.
10. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 12 : 189 198.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 34 : 939 944.
12. Exelon® (rivastigmine tartrate) Capsules and Oral Solution Prescribing Information. http://www.pharma.us.novartis.com/product/pi/pdf/ exelon.pdf (accessed November 2009).
13. Schmidt R, Alf C, Bancher C et al. Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia. Neuropsychiatry 2009 23 : 58 63.
14. Minthon L, Wallin ÅK, Eriksson S, Wattmo C, Andreasen N. Long-term rivastigmine treatment in a routine clinical setting. Acta Neurol Scand 2009 119 : 180 185.
15. Guay DR. Rivastigmine transdermal patch: role in the management of Alzheimer's disease. Consult Pharm 2008 23 : 598 609.
16. Alzheimer's Association and National Alliance for Caregiving. Families care: Alzheimer's Caregiving in the United States 2004. http://www.alz.org/ national/documents/report-familiescare.pdf (accessed November 2009).
17. Winblad B, Kawata AK, Beusterien KM et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007 22 : 485 491.
18. Mercier F, Lefevre G, Huang HL, Schmidli H, Amzal B, Appel-Dingemanse S. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007 23 : 3199 3204.